Track your comments!
[x]


When you register, comments on your articles and replies to your comments appear here. Register Now!

Sign in to your account
[x]

Not a Scientific Blogging member yet?

Register Now for a Free Scientificblogging.com Account

  • Customize your profile with pictures, banner, a blogroll and more.
  • Leave comments on articles, add other members to your friend lists, chat with people on the site.
  • Write blog posts that can be seen by hundreds of thousands of readers.

It's free and it only takes a minute!

Already a Scientific Blogging member?

Sign In Now

Banner
By News Staff | June 12th 2008 12:05 AM | Print | E-mail | Track Comments
In a report in the current issue of the journal Cell, Dr. Hugo Bellen and colleagues at Baylor College of Medicine along with Dr. Michael Miller from the University of Alabama at Birmingham show how a single mutation in the human form of the VAMP-Associated Protein B (VAPB) contributes to the nerve and muscle breakdown in flies and worms, similar to ALS in humans. They found important clues about what goes wrong in the nerves and muscles of people with amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease.

The story actually begins around 500 years ago, when a Portuguese immigrant to Brazil brought along an uninvited guest – a mutation in the gene for VAPB. That mutation leads to a rare form of inherited ALS that has so far been identified in about 200 people. ALS is a devastating disease that begins in middle age and affects nerves and muscles, destroying the individual's ability to move, talk, swallow and breathe, eventually killing the person who has it. There are an estimated 30,000 people with ALS in the United States alone. It affects people of all ethnicities worldwide.

Working in Drosophila or fruit flies, Bellen and his colleagues found that when the fly VAPB gene equivalent called VAP33 is lacking, the nerve endings are abnormal, suggesting that in its normal form, the protein associated with VAP33 is important at the junction between nerve and muscle.

Then Dr. Mayana Zatz, a professor at the University of Sao Paolo, found several large Brazilian families with a gene mutation or defect in VAPB that led to ALS. (There are mutations in other genes that cause ALS as well). At that point, a postdoctoral fellow in the Bellen lab, Dr. Hiroshi Tsuda, took over.

One of the domains of VAPB is similar to a protein in C. elegans called the major sperm protein (MSP). MSP plays a major role in readying the hermaphroditic worm to reproduce. In effect, it acts as a hormone. Tsuda dubbed the part of the VAP33 protein that resembled major sperm protein the MSP domain in its honor.

They then found that somehow the MSP domain of VAPB was being secreted and circulated in the blood throughout the human body.

"The protein is cleaved, secreted and functions as a hormone," said Bellen.

In collaboration with Miller's team at UAB, they found that MSP actually binds to ephrin receptors, regulating their role in nerve cells and muscles. (Ephrin receptors affect cell interactions, mediating when cells adhere to or repel one another as well as in clustering specific receptors present on neurons and muscle cells).

The scientists' work indicates that the mutated form of the human VAPB protein accumulates in the cell's cytoplasm. As more and more abnormal protein accumulates, both normal and abnormal protein (mutant VAPB) becomes trapped in the cell's cytoplasm. This prevents it from secreting the MSP domain, which means that the body no longer has its hormonal action. The accumulation also prevents proper protein folding, which can be toxic to neurons.

Bellen and his colleagues found that the mutant form of the protein has two effects. One, it causes the unfolded protein response that ultimately is harmful to the neurons and may affect motor function. Second, it leads to reduced secretion of MSP and a loss of the signaling mediated by ephrin receptors. They believe that these two problems work together to produce some of the key features of ALS.

Others who took part in this work include Chao Tong, Yong Qi Lin, Kriti Mohan, Claire Haueter, Anthony Zoghbi, Yadollah Harati and Justin Kwan, all of BCM, and Sung Min Han and Youfeng Yang, of the University of Alabama at Birmingham.

Funding for this work came from the Mental Retardation and Developmental Disabilities Research Center at BCM, the American Cancer Society, the Howard Hughes Medical Institute and George and Ronya Kozmetsky.

Add a comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <sup> <sub> <a> <em> <strong> <center> <cite> <code> <TH><ul> <ol> <li> <dl> <dt> <dd> <img> <br> <p> <blockquote> <strike> <object> <param> <embed> <del> <pre> <b> <i> <table> <tbody> <div> <tr> <td> <h1> <h2> <h3> <h4> <h5> <h6> <hr> <iframe>
  • Lines and paragraphs break automatically.
  • Web page addresses and e-mail addresses turn into links automatically.
CAPTCHA
If you register, you will never be bothered to prove you are human again. And you get a real editor toolbar to use instead of this HTML thing that wards off spam bots.